Kenvue Inc.
KVUE
Hisse Senetlerindeki Sıralama
#663
Kenvue Inc. functions as a global leader in the consumer health sector. The... Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Hisse Fiyatı
$19.29
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$37.05B
Değişim (1 gün)
2.23%
Değişim (1 yıl)
29.20%
Ülke
US
Ticaret Kenvue Inc. (KVUE)
Kategori
Consumer Defensive
Kenvue Inc. (KVUE) için kazanç
Jun 2026 itibarıyla kazanç TTM: $2.22B
Kenvue Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $2.22B'dir. 2023 yılında şirket $2.19B kazanç elde etti, bu 2022 yılındaki $2.64B kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Kenvue Inc. için kazanç geçmişi 2019 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $2.22B | 57.10% |
| 2024 | $1.42B | -35.39% |
| 2023 | $2.19B | -16.95% |
| 2022 | $2.64B | -9.85% |
| 2021 | $2.93B | -387.89% |
| 2020 | $-1.02B | -147.92% |
| 2019 | $2.12B | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $20.38B | 816.64% |
US
|
|
| $9.83B | 342.03% |
FR
|
|
| $2.94B | 32.30% |
US
|
|
| $1.55B | -30.27% |
IN
|
|
| $517.00M | -76.74% |
US
|
